Please enable Javascript
Menu
Subscribe
Knowledge Hubs
Conference Coverage
Roundtables
The Uromigos
Uromigos Live 2024
AUC3
Calendar
Jonathan Rosenberg, MD
Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center
Articles by Jonathan Rosenberg, MD
AUC3: A Conference Designed to Drive Consensus
Jonathan Rosenberg, MD
AUC3
|
October 7, 2024
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
View More
Bringing Experts Together to Define Gray Areas of Bladder and Kidney Cancer
Rana McKay, MD
AUC3
|
September 6, 2024
Drs. McKay and Rosenberg preview AUC3, the inaugural Advanced Urologic Cancer Consensus Conference.
View More
Panel Shares Predictions for What’s to Come in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Panelists Share Best Practices, Strategies for Community Oncologists Managing Patients on EV/Pembro
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
View More
Bladder Panel Talks Treatment Sequencing and Decisions in Different Patient Cases
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
View More
Combination Antibody-Drug Conjugate Strategy and the Future of Bladder Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
View More
Reactions to Phase 3 THOR Study: Primary End Point Not Met
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares lessons learned from the phase THOR study.
View More
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the CheckMate 901 study results.
View More
EV-302 Results and How They Compare to the JAVELIN Paradigm
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
View More
Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
View More
Panel Discusses Unmet Needs in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
View More
Dr. Jonathan Rosenberg on Whether EV Should Be a New Standard of Care for mUC
Jonathan Rosenberg, MD
Advanced Urothelial Carcinoma
|
May 9, 2023
Dr. Rosenberg discusses EV plus pembrolizumab, how the combination is being investigated in clinical trials, and toxicity.
View More